Evaluation of the metabolic response to min therapy in pancreatic cancer xenografts using a clinical PET-CT System

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 335-343

  Kayed, Hany ^a   Meyer, Patrick ^a   He, Yong ^a,b   Kraenzlin, Bettina ^c   Fink, Christian ^a   Gretz, Norbert ^c   Schoenberg, Stefan O ^a   Sadic, Maliha ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; FLUORODEOXYGLUCOSE F 18; SONIC HEDGEHOG PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERAGE STANDARDIZED UPTAKE VALUE; BONE TUMOR; CANCER CELL; CANCER CELL CULTURE; CLINICAL PROTOCOL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG METABOLISM; EX VIVO STUDY; HIP TUMOR; HUMAN; HUMAN CELL; IMAGE QUALITY; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM STANDARDIZED UPTAKE VALUE; MINIMUM STANDARDIZED UPTAKE VALUE; MOUSE; NONHUMAN; PANCREAS CANCER; SHOULDER TUMOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84867629686     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12166     Document Type: Article

References (29)

1. Pichler BJ, Wehrl HF, and Judenhofer MS (2008). Latest advances in molecular imaging instrumentation. J Nucl Med 49(suppl 2), 5S-23S.
2. Leahy R and Byrne C (2000). Recent developments in iterative image reconstruction for PET and SPECT. IEEE Trans Med Imaging 19, 257-260.
3. Czernin J, Allen-Auerbach M, and Schelbert HR (2007). Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48(suppl 1), 78S-88S.
4. Facey K, Bradbury I, Laking G, and Payne E (2007). Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11, iii-iv, xi-267.
5. Panin VY, Kehren F, Michel C, and Casey M (2006). Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging 25, 907-921.
6. Townsend DW (2008). Dual-modality imaging: combining anatomy and function. J Nucl Med 49, 938-955.
7. Huisman MC, Reder S, Weber AW, Ziegler SI, and Schwaiger M (2007). Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 34, 532-540.
8. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, and Wahl RL (2003). Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer Res 63, 6252-6257.
9. Aide N, Desmonts C, Briand M, Meryet-Figuiere M, and Poulain L (2010). Highthroughput small animal PET imaging in cancer research: evaluation of the capability of the Inveon scanner to image four mice simultaneously. Nucl Med Commun 31, 851-858.
10. Wolf G and Abolmaali N (2009). Imaging tumour-bearing animals using clinical scanners. Int J Radiat Biol 85, 752-762.
11. Revheim ME, Roe K, Bruland OS, Bach-Gansmo T, Skretting A, and Seierstad T (2011). Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol 13, 1234-1240.
12. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, et al. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856.
13. Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, Berberat PO, Giese N, Esposito I, Giese T, BuchlerMW, et al. (2004). Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer 110, 668-676.
14. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, et al. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67, 2187-2196.
15. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, et al. (2008). Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57, 1420-1430.
16. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, Berger MR, Altmann A, and van Kaick G (1994). FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21, 827-834.
17. Incardona JP, Gaffield W, Kapur RP, and Roelink H (1998). The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 125, 3553-3562.
18. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, et al. (2007). Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 97, 1432-1440.
19. Seemann MD, Beck R, and Ziegler S (2006). In vivo tumor imaging in mice using a state-of-the-art clinical PET/CT in comparison with a small animal PET and a small animal CT. Technol Cancer Res Treat 5, 537-542.
20. De Ruysscher D, Wanders S, Minken A, Lumens A, Schiffelers J, Stultiens C, Halders S, Boersma L, Baardwijk A, Verschueren T, et al. (2005). Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 77, 5-10.
21. De RuysscherD, Wanders S, van Haren E, HochstenbagM, GeeraedtsW, Utama I, Simons J, Dohmen J, Rhami A, Buell U, et al. (2005). Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62, 988-994.
22. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin P, and De Ruysscher D (2006). The current status of FDGPET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32, 245-260.
23. van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, van Suylen RJ, Dekker A, Dehing-Oberije C, Houben R, et al. (2007). PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68, 771-778.
24. Michl P, Pauls S, and Gress TM (2006). Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 20, 227-251.
25. Grassetto G and Rubello D (2011). Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol 34, 111-114.
26. Jemal A, Siegel R, Xu J, and Ward E (2011). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
27. Xu FG, Ma QY, and Wang Z (2009). Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. Cancer Lett 283, 119-124.
28. Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, Scott MP, Pennica D, Goddard A, Phillips H, et al. (1996). The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 384, 129-134.
29. Dominguez M, Brunner M, Hafen E, and Basler K (1996). Sending and receiving the hedgehog signal: control by the Drosophila Gli protein Cubitus interruptus. Science 272, 1621-1625.